Vinorelbine

• Description :

  Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

• Product Name Alternative :

  KW-2307 base

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; Microtubule/Tubulin

• Type :

  Natural Products

• Related Pathways :

  Autophagy; Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/vinorelbine.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(C[C@@](C=C(CC)C7)([H])C[N@]7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O

• Molecular Formula :

  C45H54N4O8

• Molecular Weight :

  778.93

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60 (1) :225-32.|[2]Liu XM, et al. Unique induction of p21 (WAF1/CIP1) expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89 (8) :1566-73.|[3]Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18 (4) :536-9.|[4]Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27 (4) :943-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  Launched

• Citation 01 :

  Am J Cancer Res. 2021 Apr 15;11 (4) :1428-1445.|Biochem Pharmacol. 2020 May;175:113865.|Cancers (Basel) . 2021 Jul 2;13 (13) :3323.|J Bone Oncol. 2021 Sep 20:30:100391.|Microsyst Nanoeng. 2021 May 24:7:38.|Acta Pharmacol Sin. 2024 Oct;45 (10) :2174-2185.|Adv Ther. 2024 Jul 18.|Biochem Biophys Res Commun. 2020 May 21;526 (1) :154-157.|bioRxiv. 2025 Aug 27.|Cell Mol Immunol. 2023 Jan;20 (1) :51-64.|Cell Rep Med. 2025 Apr 2:102053.|EBioMedicine. 2021 Aug:70:103510.|Int J Cancer. 2024 Jul 15;155 (2) :324-338.|iScience. 2022 Sep 6;25 (10) :105081.|Microb Cell Fact. 2025 Jan 30;24 (1) :34.|Res Sq. 2025 May 16:rs.3.rs-6590535.|Sci Adv. 2023 Jun 2;9 (22) :eadc9273.|Transl Lung Cancer Res. 2024 Oct 31;13 (10) :2698-2712.

• CAS Number :

  [71486-22-1]